ATAI
Price
$7.34
Change
-$0.01 (-0.14%)
Updated
Sep 3 closing price
Capitalization
2.72B
70 days until earnings call
Intraday BUY SELL Signals
COUR
Price
$6.07
Change
-$0.04 (-0.65%)
Updated
Sep 3, 03:59 PM (EDT)
Capitalization
1.62B
49 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATAI vs COUR

ATAI vs COUR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ATAI vs. COUR commentary
Sep 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATAI is a Hold and COUR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2026
Stock price -- (ATAI: $7.35 vs. COUR: $6.11)
Brand notoriety: ATAI and COUR are both not notable
ATAI represents the Biotechnology, while COUR is part of the Other Consumer Specialties industry
Current volume relative to the 65-day Moving Average: ATAI: 88% vs. COUR: 67%
Market capitalization -- ATAI: $2.72B vs. COUR: $1.62B
ATAI [@Biotechnology] is valued at $2.72B. COUR’s [@Other Consumer Specialties] market capitalization is $1.62B. The market cap for tickers in the [@Biotechnology] industry ranges from $141.42B to $0. The market cap for tickers in the [@Other Consumer Specialties] industry ranges from $9.44B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B. The average market capitalization across the [@Other Consumer Specialties] industry is $1.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATAI’s FA Score shows that 1 FA rating(s) are green whileCOUR’s FA Score has 0 green FA rating(s).

  • ATAI’s FA Score: 1 green, 4 red.
  • COUR’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATAI and COUR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATAI’s TA Score shows that 2 TA indicator(s) are bullish while COUR’s TA Score has 6 bullish TA indicator(s).

  • ATAI’s TA Score: 2 bullish, 6 bearish.
  • COUR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, COUR is a better buy in the short-term than ATAI.

Price Growth

ATAI (@Biotechnology) experienced а -0.54% price change this week, while COUR (@Other Consumer Specialties) price change was +0.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.13%. For the same industry, the average monthly price growth was +5.15%, and the average quarterly price growth was +2203.93%.

The average weekly price growth across all stocks in the @Other Consumer Specialties industry was -1.14%. For the same industry, the average monthly price growth was -4.12%, and the average quarterly price growth was -10.39%.

Reported Earning Dates

ATAI is expected to report earnings on Nov 12, 2026.

COUR is expected to report earnings on Oct 22, 2026.

Industries' Descriptions

@Biotechnology (-3.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Other Consumer Specialties (-1.14% weekly)

‘Other Consumer Specialties’ represents an industry that typically sells durable consumer products, but do not have a classification in another category. The products include jewelry, smoke detectors, watches, collectibles and safety products. MSA Safety (makes products which enhances the safety and health of workers and protect facility infrastructures), Matthews International (memorialization business), Fitbit (makes wireless-enabled wearable technology devices that gauge data such as the number of steps walked, heart rate, quality of sleep), and Fossil Group (makes watches and accessories) have some of the largest market caps in this group.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATAI($2.72B) has a higher market cap than COUR($1.62B). ATAI YTD gains are higher at: 79.707 vs. COUR (-16.984). COUR has higher annual earnings (EBITDA): -59.1M vs. ATAI (-662.1M). COUR has more cash in the bank: 790M vs. ATAI (231M). ATAI has less debt than COUR: ATAI (2M) vs COUR (3.1M). COUR has higher revenues than ATAI: COUR (774M) vs ATAI (3.49M).
ATAICOURATAI / COUR
Capitalization2.72B1.62B168%
EBITDA-662.1M-59.1M1,120%
Gain YTD79.707-16.984-469%
P/E RatioN/AN/A-
Revenue3.49M774M0%
Total Cash231M790M29%
Total Debt2M3.1M65%
FUNDAMENTALS RATINGS
ATAI: Fundamental Ratings
ATAI
OUTLOOK RATING
1..100
45
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
12
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATAICOUR
RSI
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 15 days ago
83%
Bullish Trend 4 days ago
74%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ATAI
Daily Signal:
Gain/Loss:
COUR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PLTD5.370.30
+5.92%
Direxion Daily PLTR Bear 1X Shares
PSC68.910.54
+0.79%
Principal US Small Cap ETF
AOTS23.25N/A
N/A
AOT Software Platform ETF
FLTB49.78-0.01
-0.01%
Fidelity Limited Term Bond ETF
PUSH50.30-0.05
-0.10%
PGIM Ultra Short Municipal Bond ETF